Kronos Bio Announces Participation in Cowen 42nd Annual Health Care Conference

Rhea-AI Summary

Kronos Bio, Inc. (Nasdaq: KRON), focused on cancer therapies, will participate in the Cowen 42nd Annual Health Care Conference from March 7-9, 2022. CEO Norbert Bischofberger, Ph.D., is scheduled to join the "Novel Oncology Targets" panel on March 7 at 12:50 p.m. ET. A live webcast of the discussion will be available on the company's website, with a replay archived for 30 days. Kronos is developing treatments targeting dysregulated transcription in cancer, including its lead compound, entospletinib, for NPM1-mutated acute myeloid leukemia.

Positive

• Participation in a significant healthcare conference, which could enhance visibility and investor interest.
• Panel discussion focused on novel oncology targets may indicate innovative developments in cancer therapies.

Negative

• None.

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced participation in the Cowen 42nd Annual Health Care Conference, a virtual event taking place March 7-9, 2022.

Kronos Bio President and Chief Executive Officer Norbert Bischofberger, Ph.D., will participate in the “Novel Oncology Targets” panel discussion on Monday, March 7, at 12:50 p.m. ET. A live webcast of the panel will be available on the Investors & Media section of the company’s website at www.kronosbio.com. A replay of the webcast will be archived and available for 30 days following the event.

About Kronos Bio, Inc.
Kronos Bio is an integrated discovery through late-stage clinical development biopharmaceutical company, focused on developing therapies that target the dysregulated transcription that causes cancer and other serious diseases. Kronos Bio’s lead investigational compound is entospletinib, an orally administered, selective inhibitor targeting spleen tyrosine kinase (SYK) in clinical development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML) in combination with intensive chemotherapy. The company is also developing KB-0742, an orally administered inhibitor of cyclin dependent kinase 9 (CDK9), in Phase 1/2 clinical development for the treatment of MYC-amplified or overexpressing solid tumors.

Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit www.kronosbio.com or follow the company on LinkedIn.

Company Contact:
Marni Kottle
Kronos Bio
650-900-3450
mkottle@kronosbio.com

Investors:
Claudia Styslinger
Argot Partners
212-600-1902
kronosbio@argotpartners.com

Media:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com

 

FAQ

When is Kronos Bio participating in the Cowen 42nd Annual Health Care Conference?

Kronos Bio will participate in the Cowen 42nd Annual Health Care Conference from March 7-9, 2022.

Who from Kronos Bio will be speaking at the Cowen Conference?

Kronos Bio CEO Norbert Bischofberger, Ph.D., will speak on the "Novel Oncology Targets" panel.

What time is Kronos Bio's panel discussion at the Cowen Conference?

The panel discussion featuring Kronos Bio is scheduled for March 7 at 12:50 p.m. ET.

How can I access the webcast of Kronos Bio's panel discussion?

The live webcast can be accessed on Kronos Bio's website, with a replay available for 30 days after the event.

What is Kronos Bio's lead investigational compound?

Kronos Bio's lead investigational compound is entospletinib, targeting NPM1-mutated acute myeloid leukemia.